Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT ID: NCT05841472
This clinical trial is studying a new treatment combination for patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The treatment involves using a drug called camr...
Recruiting
Phase: PHASE2
Type: interventional
Locations: Seoul, , Korea, Republic Of, Seoul, , Korea, Republic Of +6 more